参考文献

参考文献

［1］Chua MLK，Wee JTS，Hui EP，et al.Nasopharyngeal carcinoma［J］.Lancet，2016，387（10022）：1012-1024.

［2］Lee HM，Okuda KS，González FE，et al.Current Perspectives on Nasopharyngeal Carcinoma［J］.Adv Exp Med Biol，2019，1164：11-34.

［3］Bray F，Ferlay J，Soerjomataram I，et al. Global cancer statistics 2018：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin，2018，68（6）：394-424.

［4］Wei KR，Zheng RS，Zhang SW，et al.Nasopharyngeal carcinoma incidence and mortality in China in 2010［J］.Chin J Cancer，2014，33（8）：381-387.

［5］Foo KF，Tan EH，Leong SS，et al. Gemcitabine in metastatic nasopharyngeal carcinoma of the undifferentiated type［J］.Ann Oncol，2002，13（1）：150-156.

［6］Ahmad A，Stefani S.Distant metastases of nasopharyngeal carcinoma：a study of 256 male patients［J］.J Surg Oncol，1986，33（3）：194-197.

［7］Pan C，Tao Y，Zhao M，et al.Comparative serum proteomic analysis involving liver organ-specific metastasis-associated proteins of nasopharyngeal carcinoma［J］.Exp Ther Med，2012，3（6）：1055-1061.

［8］Qu W，Li S，Zhang M，et al. Pattern and prognosis of distant metastases in nasopharyngeal carcinoma：A large-population retrospective analysis［J］.Cancer Med，2020，9（17）：6147-6158.

［9］Lee AW，Ng WT，Chan YH，et al.The battle against nasopharyngeal cancer［J］.Radiother Oncol，2012，104（3）：272-278.

［10］Ahn MJ，D'Cruz A，Vermorken JB，et al.Clinical recommendations for defining platinum unsuitable head and neck cancer patient populations on chemoradiotherapy：A literature review［J］.Oral Oncol，2016，53：10-16.

［11］Peng G，Wang T，Yang KY，et al.A prospective，randomized study comparing outcomes and toxicities of intensity-modulated radiotherapy vs. conventional two-dimensional radiotherapy for the treatment of nasopharyngeal carcinoma［J］.Radiother Oncol，2012，104（3）：286-293.

［12］Li XY，Chen QY，Sun XS，et al.Ten-year outcomes of survival and toxicity for a phase Ⅲ randomised trial of concurrent chemoradiotherapy versus radiotherapy alone in stageⅡnasopharyngeal carcinoma［J］.Eur J Cancer，2019，110：24-31.

［13］Guo Q，Lu T，Lin S，et al.Long-term survival of nasopharyngeal carcinoma patients with Stage Ⅱ in intensity-modulated radiation therapy era［J］.Jpn J Clin Oncol，2016，46（3）：241-247.

［14］Lee AW，Tung SY，Chua DT，et al.Randomized trial of radiotherapy plus concurrent-adjuvant chemotherapy vs radiotherapy alone for regionally advanced nasopharyngeal carcinoma［J］.J Natl Cancer Inst，2010，102（15）：1188-1198.

［15］Tang LQ，Chen DP，Guo L，et al.Concurrent chemoradiotherapy with nedaplatin versus cisplatin in stageⅡ-ⅣB nasopharyngeal carcinoma：an open-label，non-inferiority，randomised phase 3 trial［J］.Lancet Oncol，2018，19（4）：461-473.

［16］You R，Sun R，Hua YJ，et al. Cetuximab or nimotuzumab plus intensity-modulated radiotherapy versus cisplatin plus intensitymodulated radiotherapy for stageⅡ-Ⅳb nasopharyngeal carcinoma［J］.Int J Cancer，2017，141（6）：1265-1276.

［17］Ribassin-Majed L，Marguet S，Lee AWM，et al.What is the best treatment of locally advanced nasopharyngeal carcinoma？an individual patient data network meta-analysis［J］.J Clin Oncol，2017，35（5）：498-505.

［18］Sun Y，Li WF，Chen NY，et al. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma：a phase 3，multicentre，randomised controlled trial［J］.Lancet Oncol，2016，17（11）：1509-1520.

［19］Chen L，Hu CS，Chen XZ，et al.Adjuvant chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma：Long-term results of a phase 3 multicentre randomised controlled trial［J］.Eur J Cancer，2017，75：150-158.(https://www.daowen.com)

［20］Au E，Ang P T.A phaseⅡtrial of 5-fluorouracil and cisplatinum in recurrent or metastatic nasopharyngeal carcinoma［J］. Ann Oncol，1994，5（1）：87-89.

［21］Zhang L，Huang Y，Hong S，et al.Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma：a multicentre，randomised，open-label，phase 3 trial［J］.Lancet，2016，388（10054）：1883-1892.

［22］Ji JH，Korean Cancer Study Group（KCSG），Yun T，et al.A prospective multicentre phaseⅡstudy of cisplatin and weekly docetaxel as first-line treatment for recurrent or metastatic nasopharyngeal cancer（KCSG HN07-01）［J］.Eur J Cancer，2012，48（17）：3198-3204.

［23］Ma BBY，Lim WT，Goh BC，et al.Antitumor activity of nivolumab in recurrent and metastatic nasopharyngeal carcinoma：an international，multicenter study of the mayo clinic phase 2 consortium（NCI-9742）［J］.J Clin Oncol，2018，36（14）：1412-1418.

［24］Tian YM，Zeng L，Wang FH，et al. Prognostic factors in nasopharyngeal carcinoma with synchronous liver metastasis：a retrospective study for the management of treatment［J］.Radiat Oncol，2013，8：272.

［25］Ong YK，Heng DM，Chung B，et al.Design of a prognostic index score for metastatic nasopharyngeal carcinoma［J］.Eur J Cancer，2003，39（11）：1535-1541.

［26］Huang J，Li Q，Zheng Y，et al. Partial hepatectomy for liver metastases from nasopharyngeal carcinoma：a comparative study and review of the literature［J］.BMC Cancer，2014，14：818.

［27］Adam R，Chiche L，Aloia T，et al.Hepatic resection for noncolorectal nonendocrine liver metastases：analysis of 1，452 patients and development of a prognostic model［J］.Ann Surg，2006，244（4）：524-535.

［28］Goéré，D，Elias D.Resection of liver metastases from non-colorectal non-endocrine primary tumours［J］.Eur J Surg Oncol，2008，34（3）：281-288.

［29］Feng Y，Zhao YM，Li WW，et al.Hepatic resection prolongs overall survival in the selected patients with nasopharyngeal carcinoma liver metastases［J］.Eur J Surg Oncol，2022，48（10）：2202-2211.

［30］Peng C，Zhou C，Li G，et al. Hepatic artery infusion pump for nasopharyngeal carcinoma with liver metastasis［J］. Clin Exp Metastasis，2020，37（2）：333-339.

［31］Strohmeyer T，Haugeberg G，Lierse W.Angioarchitecture and blood supply of micro-and macrometastases in human livers.An anatomicpathological investigation using injection-techniques［J］.J Hepatol，1987，4（2）：181-189.

［32］Li W，Bai Y，Wu M，Shen L，et al. Combined CT-guided radiofrequency ablation with systemic chemotherapy improves the survival for nasopharyngeal carcinoma with oligometastasis in liver：Propensity score matching analysis［J］.Oncotarget，2017，8（32）：52132-52141.

［33］Pan C，Wu P，Yu J，et al. CT-guided radiofrequency ablation prolonged metastatic survival in patients with liver metastases from nasopharyngeal carcinoma［J］.Int J Hyperthermia，2011，27（6）：549-554.

［34］Jin Y，Cai YC，Cao Y，et al.Radiofrequency ablation combined with systemic chemotherapy in nasopharyngeal carcinoma liver metastases improves response to treatment and survival outcomes［J］.J Surg Oncol，2012，106（3）：322-326.

［35］Tsoulfas G，Pramateftakis MG.Management of rectal cancer and liver metastatic disease：which comes first？［J］.Int J Surg Oncol，2012，2012：196908.

［36］Schwarz C，Kaczirek K，Bodingbauer M. Liver resection for noncolorectal metastases［J］.Eur Surg，2018，50（3）：113-116.

［37］Lin JC，Wang WY，Chen KY，et al.Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma［J］.N Engl J Med，2004，350（24）：2461-2470.

［38］Chan AT，Lo YM，Zee B，et al.Plasma epstein-barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma［J］.J Natl Cancer Inst，2002，94（21）：1614-1619.